Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 14 points (0.1%) at 14,951 as of Friday, Sept. 6, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,968 issues advancing vs. 907 declining with 132 unchanged. The Health Services industry currently sits up 0.1% versus the S&P 500, which is up 0.2%. A company within the industry that fell today was Emeritus Corporation ( ESC), up 8.6%. Top gainers within the industry include HCA Holdings ( HCA), up 2.3%, Grifols ( GRFS), up 1.5%, C.R. Bard ( BCR), up 0.9%, Express Scripts ( ESRX), up 0.9% and Zimmer Holdings ( ZMH), up 0.6%. TheStreet would like to highlight 5 stocks pushing the industry lower today: 5. Mindray Medical International ( MR) is one of the companies pushing the Health Services industry lower today. As of noon trading, Mindray Medical International is down $0.80 (-2.0%) to $39.97 on average volume. Thus far, 415,494 shares of Mindray Medical International exchanged hands as compared to its average daily volume of 706,500 shares. The stock has ranged in price between $39.64-$41.02 after having opened the day at $40.95 as compared to the previous trading day's close of $40.77. Mindray Medical International Limited, through its subsidiary, Shenzhen Mindray, develops, manufactures, and markets medical devices worldwide. It operates in three segments: Patient Monitoring and Life Support Products, In-Vitro Diagnostic Products, and Medical Imaging Systems. Mindray Medical International has a market cap of $4.6 billion and is part of the health care sector. Shares are up 24.7% year to date as of the close of trading on Thursday. Currently there are 4 analysts that rate Mindray Medical International a buy, 1 analyst rates it a sell, and 3 rate it a hold. TheStreet Ratings rates Mindray Medical International as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year, impressive record of earnings per share growth and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Mindray Medical International Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.